Nurlan Nigmatulin, the Chairman of the Mazhilis of the Parliament of the Republic of Kazakhstan, believes that Kazakhstani pharmaceutical market strongly depends on imports. According to Mr. Nigmatulin, in the past year, the imports of medicines to Kazakhstan exceeded the exports 43-fold.
Moreover, many medicinal products registered in Kazakhstan are available only in the CIS countries and their countries of origin (Pakistan, India, etc.). However, all these medicines are not registered in the countries of the Organization for Economic Cooperation and Development as they do not meet their quality standards. And as a result, the qualitative structure of imports did not change significantly over the past five years, said the Chairman of the Mazhilis.
According to Mr. Nigmatulin, in 2011-2016, the share of products made by Kazakhstan manufacturers did not increase in the structure of domestic consumption and, in 2016, amounted to only 9.6%. In the national Gross Domestic Product, it stands at only 0.09% while, in the developed countries, it ranges from 1.5% to 5%.
The Chairman of the Mazhilis also noted a number of negative factors that impede the entry of original medicines from Kazakhstan to the world market. In particular, this results from the fact that many pharmaceutical companies in Kazakhstan are not ready to produce the medicinal products in accordance with the requirements of international standards. In addition, the quality of Kazakhstani medicines is low.